Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy

Silva, Ildefonso; Andrade, Luciana Nogueira de Sousa; Jancar, Sônia; Chammas, Roger

doi:10.6061/clinics/2018/e792s

Cited by 16 publications

(28 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The LOC100300716 gene is the immunoglobulin heavy variable 4-38-2 that is involved in antigen recognition and is conserved in human and other primates. The PTAFR receptor binds platelet activating factor (PAF), which has been implicated in a number of diseases and disorders like asthma, allergies and is also a lipid mediator of inflammatory responses [46]. These genes underscore the potential involvement that immune responses and inflammatory pathways seem to have with feed efficiency in the mesenteric adipose tissue.…”

Section: Genes Identified For the Gain X Intake Interactionmentioning

confidence: 99%

Genes associated with body weight gain and feed intake identified by meta-analysis of the mesenteric fat from crossbred beef steers

et al. 2020

View full text Add to dashboard Cite

Mesenteric fat is a visceral fat depot that increases with cattle maturity and can be influenced by diet. There may be a relationship between the accumulation of mesenteric fat and feed efficiency in beef cattle. The purpose of this study was to identify genes that may be differentially expressed in steers with high and low BW gain and feed intake. RNA-Seq was used to evaluate the transcript abundance of genes in the mesenteric fat from a total of 78 steers collected over 5 different cohorts. A meta-analysis was used to identify genes involved with gain, feed intake or the interaction of both phenotypes. The interaction analysis identified 11 genes as differentially expressed. For the main effect of gain, a total of 87 differentially expressed genes (DEG) were identified (P ADJ <0.05), and 24 were identified in the analysis for feed intake. Genes identified for gain were involved in functions and pathways including lipid metabolism, stress response/protein folding, cell proliferation/growth, axon guidance and inflammation. The genes for feed intake did not cluster into pathways, but some of the DEG for intake had functions related to inflammation, immunity, and/or signal transduction (JCHAIN, RIPK1, LY86, SPP1, LYZ, CD5, CD53, SRPX, and NF2). At P ADJ <0.1, only 4 genes (OLFML3, LOC100300716, MRPL15, and PUS10) were identified as differentially expressed in two or more cohorts, highlighting the importance of evaluating the transcriptome of more than one group of animals and incorporating a meta-analysis. This meta-analysis has produced many mesenteric fat DEG that may be contributing to gain and feed intake in cattle. OPEN ACCESSCitation: Lindholm-Perry AK, Freetly HC, Oliver WT, Rempel LA, Keel BN (2020) Genes associated with body weight gain and feed intake identified by meta-analysis of the mesenteric fat from crossbred beef steers. PLoS ONE 15(1): e0227154. https://

show abstract

Section: Genes Identified For the Gain X Intake Interactionmentioning

confidence: 99%

Genes associated with body weight gain and feed intake identified by meta-analysis of the mesenteric fat from crossbred beef steers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For example, RNA-seq indicated a 72-fold increase of the PTAFR gene in the A549/DDP cells. It has been reported that activated PTAFR-dependent pathways in tumor cells affect the tumor microenvironment and the phenotype of the tumor-associated macrophages to promote tumor growth 90 , 91 . Of note, we did not find any previous study on PTAFR’s regulatory effect on A549/DDP cells.…”

Section: Discussionmentioning

confidence: 99%

Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance

Hossian

Zahra

Poudel

et al. 2021

Sci Rep

View full text Add to dashboard Cite

This study aims to identify pathway involvement in the development of cisplatin (cis-diamminedichloroplatinum (II); CDDP) resistance in A549 lung cancer (LC) cells by utilizing advanced bioinformatics software. We developed CDDP-resistant A549 (A549/DDP) cells through prolonged incubation with the drug and performed RNA-seq on RNA extracts to determine differential mRNA and miRNA expression between A549/DDP and A549 cells. We analyzed the gene dysregulation with Ingenuity Pathway Analysis (IPA; QIAGEN) software. In contrast to prior research, which relied on the clustering of dysregulated genes to pathways as an indication of pathway activity, we utilized the IPA software for the dynamic evaluation of pathway activity depending on the gene dysregulation levels. We predicted 15 pathways significantly contributing to the chemoresistance, with several of them to have not been previously reported or analyzed in detail. Among them, the PKR signaling, cholesterol biosynthesis, and TEC signaling pathways are included, as well as genes, such as PIK3R3, miR-34c-5p, and MDM2, among others. We also provide a preliminary analysis of SNPs and indels, present exclusively in A549/DDP cells. This study's results provide novel potential mechanisms and molecular targets that can be explored in future studies and assist in improving the understanding of the chemoresistance phenotype.

show abstract

“…The receptor induces downstream signaling via EGFR/Src/FAK/Paxillin 11 . Known PAFR antagonists are amongst others: WEB-2086, Ginkgolide B, and Rupatadine 16,[34][35][36] . Rupatadine is a PAFR antagonist that is clinically used as an antihistaminic drug 17,37 .…”

Section: Discussionmentioning

confidence: 99%

The Platelet-activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and its Experimental Inhibition by Rupatadine

Deuster

Kahaly

Schmoeckel

et al. 2021

Preprint

View full text Add to dashboard Cite

The platelet-activating factor receptor (PAFR) and its ligand (PAF) are important inflammatory mediators that are overexpressed in ovarian cancer. The receptor is an important player in ovarian cancer development. In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian cancer (EOC) and the potential use of its antagonist, Rupatadine as an experimental treatment. Tissue microarrays of ovarian cancer patients, most markedly those with a non-mucinous subtype, immunohistochemically overexpressed PAFR. Elevated cytoplasmic PAFR expression was found to significantly and independently impair patients’ overall and recurrence-free survival (OS: median 83.48 vs. 155.03 months; p=0.022; RFS: median 164.46 vs. 78.03 months; p=0.015). In vitro, especially the serous ovarian cancer subtypes displayed an elevated PAFR gene and protein expression. siRNA knockdown of PAFR decreased cell proliferation significantly, thus confirming the receptor's protumorigenic effect on ovarian cancer cells. The clinically approved PAFR antagonist Rupatadine effectively inhibited in vitro cell proliferation and migration of ovarian cancer cells. PAFR is a prognostic marker in ovarian cancer patients and its inhibition through Rupatadine may have important therapeutic implications in the therapy of ovarian cancer patients.

show abstract

Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy

Cited by 16 publications

References 71 publications

Genes associated with body weight gain and feed intake identified by meta-analysis of the mesenteric fat from crossbred beef steers

Genes associated with body weight gain and feed intake identified by meta-analysis of the mesenteric fat from crossbred beef steers

Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance

The Platelet-activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and its Experimental Inhibition by Rupatadine

Contact Info

Product

Resources

About